Antipsychotic polypharmacy and high-dose prescription in schizophrenia: A 5-year comparison

Australian and New Zealand Journal of Psychiatry

Volumn 48, Issue 1, 2014, Pages 52-60

  Roh, Daeyoung ^a   Chang, Jhin Goo ^a   Kim, Chan Hyung ^a,b   Cho, Hyun Sang ^a,b   An, Suk Kyoon ^a,b   Jung, Young Chul ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Antipsychotics; haloperidol; high dose antipsychotics; polypharmacy; quetiapine; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DRUG MEGADOSE; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; SCHIZOPHRENIA; YOUNG ADULT;

ANTIPSYCHOTICS; HALOPERIDOL; HIGH-DOSE ANTIPSYCHOTICS; POLYPHARMACY; QUETIAPINE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; POLYPHARMACY; QUINOLONES; REPUBLIC OF KOREA; SCHIZOPHRENIA;

EID: 84891291044     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413488221     Document Type: Article

References (52)

1. Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. Journal of Clinical Psychiatry. 2010 ; 71: 103-108
2. Barbui C, Nose M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. Journal of Clinical Psychopharmacology. 2005 ; 25: 521-526
3. Barbui C, Nose M, Mazzi MA, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology. 2006 ; 21: 355-362
4. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs. 1999 ; 12: 179-188
5. Centorrino F, Fogarty KV, Sani G, et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Human Psychopharmacology: Clinical and Experimental. 2005 ; 20: 485-492
6. Centorrino F, Ventriglio A, Vincenti A, et al. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Human Psychopharmacology: Clinical and Experimental. 2010 ; 25: 179-186
7. Cho HS, Kwon JS, Bahk WM, et al. The feasibility test of Korean medication algorithm for the treatment with schizophrenic patients (IV): influences of a history of antipsychotic treatment on effectiveness and algorithm application. Korean Journal of Psychopharmacology. 2006 ; 17: 162-173
8. Chong SA, Sachdev P, Mahendran R, et al. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Australasian Psychiatry. 2000 ; 34: 988-991
9. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: implications for state mental health policy. Schizophrenia Bulletin. 2002 ; 28: 75-84
10. Correll CU. Real-life dosing with second-generation antipsychotics. Journal of Clinical Psychiatry. 2005 ; 66: 1610-1611
11. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin. 2009 ; 35: 443-457
12. Correll CU, Shaikh L, Gallego JA, et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research. 2011 ; 131: 58-62
13. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology. 2004 ; 24: 192
14. Diaz FJ, De Leon J. Excessive antipsychotic dosing in 2 U.S. State hospitals. Journal of Clinical Psychiatry. 2002 ; 63: 998-1003
15. Dolder CR, Mckinsey J. Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit. Journal of Psychiatric Practice. 2011 ; 17: 368-374
16. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry. 2011 ; 168: 702-708
17. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005 ; 5: 26
18. Freudenreich O, Goff D. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica. 2002 ; 106: 323-330
19. Gaebel W, Weinmann S, Sartorius N, et al. Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry. 2005 ; 187: 248-255
20. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research. 2012a ; 138: 18-28
21. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety. 2012b ; 11: 527-542
22. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry. 2004 ; 65: 1377-1388
23. Goff DC, Dixon L. Antipsychotic polypharmacy: Are two ever better than one?. American Journal of Psychiatry. 2011 ; 168: 667-669
24. Gugger JJ, Cassagnol M. Low-dose quetiapine is not a benign sedative-hypnotic agent. American Journal on Addictions. 2008 ; 17: 454-455
25. Harrington M, Lelliott P, Paton C, et al. Variation between services in polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin. 2002 ; 26: 418-420
26. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of General Psychiatry. 2000 ; 57: 553-559
27. López de Torre A, Lertxundi U, Hernández R, et al. Antipsychotic polypharmacy: a needle in a haystack?. General Hospital Psychiatry. 2012 ; 34: 423-432
28. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry. 2004 ; 161: 1-56
29. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin. 1998 ; 24: 1-10
30. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005 ; 353: 1209-1223
31. McGorry P, Killackey E, Lambert T, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry. 2005 ; 39: 1-30
32. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry. 2010 ; 67: 26-36
33. Pandurangi AK, Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. Journal of Psychiatric Practice. 2008 ; 14: 345-367
34. Procyshyn RM, Honer WG, Wu T, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. Journal of Clinical Psychiatry. 2010 ; 71: 566-573
35. Rey MJ, Schulz P, Costa C, et al. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology. 1989 ; 4: 95-104
36. Rijcken CAW, Monster T, Brouwers JRBJ, et al. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?. Journal of Clinical Psychopharmacology. 2003 ; 23: 657-659
37. Consensus statement on the use of high-dose antipsychotic medication. Council Report CR138. London: RCP ; 2006 :
38. Santone G, Bellantuono C, Rucci P, et al. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiology and Drug Safety. 2011 ; 20: 441-449
39. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry. 2004 ; 65: 1597-1600
40. Sim K, Su A, Chan YH, et al. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry and Clinical Neurosciences. 2004a ; 58: 324-329
41. Sim K, Su A, Leong J, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry. 2004b ; 37: 175-179
42. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. British Journal of Clinical Pharmacology. 2009 ; 67: 110-117
43. Sim K, Yong KH, Chan YH, et al. Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008). International Journal of Neuropsychopharmacology. 2011 ; 14: 1157-1164
44. Siris SG. Depression in Schizophrenia: perspective in the era of "atypical" antipsychotic agents. American Journal of Psychiatry. 2000 ; 157: 1379-1389
45. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret. Journal of Clinical Psychiatry. 1999 ; 60: 425-426
46. Taylor D, Paton C, Kapur S Prescribing guidelines in psychiatry. Oxford: Wiley Blackwell ; 2012 :
47. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry. 2012 ; 69: 476-483
48. Waterreus A, Morgan VA, Castle D, et al. Medication for psychosis-consumption and consequences: the second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 762-773
49. Weiden PJ, Scheifler P, McEvoy J, et al. Expert consensus treatment guidelines for schizophrenia: a guide for patients and families. Journal of Clinical Psychiatry. 1999 ; 60: 73-80
50. Guidelines for Anatomical Therapeutic Chemical (ATC) classification and DDD assignment. Oslo: WHO ; 2002 :
51. Xiang YT, Wang CY, Si TM, et al. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry. 2012 ; 45: 7-12
52. Zhornitsky S, Potvin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. International Clinical Psychopharmacology. 2011 ; 26: 183-192